DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

RTTNews | 542 hari yang lalu
Stocktwits
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.

Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.

DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.

Teg: DRRX CRL
Stocktwits
read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 386 hari yang lalu
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews | 840 hari yang lalu
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1121 hari yang lalu
DURECT Appoints Timothy Papp As New CFO

DURECT Appoints Timothy Papp As New CFO

Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews | 1150 hari yang lalu
FTSE 100 Down 0.4% In Cautious Trade

FTSE 100 Down 0.4% In Cautious Trade

After a slightly positive start, U.K. stocks turned weak Thursday morning with investors treading cautiously amid a lack of triggers. Shares of financials and utilities companies are struggling a bit.
RTTNews | 5 minit yang lalu
CAC Up Slightly; Pernod Ricard Rises On Earnings

CAC Up Slightly; Pernod Ricard Rises On Earnings

The French market is up slightly a little past noon on Thursday, supported by data showing an increase in new car registrations in Europe, and stronger-than-expected results and forecast from AI chip major Nvidia.
RTTNews | 24 minit yang lalu
Alat
Kalendar Ekonomi
Waktu pasaran
Kadar faedah
Kalendar cuti
Pasaran Forex
Volatiliti Forex
Korelasi Forex
Berita Forex
Analisis Forex
Data COT
Kecairan
Kalkulator Forex
Peta Panas Forex
Peta haba indikator
Komuniti
Komuniti
Sistem
Sistem Paling Popular
Strategi
Peraduan
Carta Forex
Sentimen Forex
Petunjuk Outlook
Ulasan
Broker
Firma Dagangan Proprietari
Perkhidmatan VPS
Penyedia Isyarat
Perkhidmatan Pengaturcaraan EA
Program Afiliasi
Perkhidmatan PAMM Broker
Perkhidmatan Program Rebat
Platform Dagangan
Penasihat Pakar
Pertukaran Kripto
Kursus dagangan
Broker
Spreads Forex
Sebut Harga Forex Broker
Pertukaran Broker Forex
Jumlah Broker Forex
Promosi Broker Forex
Siaran Akhbar
Platform
Widget
Ciri-ciri
API
RSS
Stock Portfolio
Affiliate Software
Carta Lanjutan
Sokongan
Soalan Lazim
Bantuan
Hubungi Kami
Laporkan pepijat!
Mengenai
Blog
&salin; 2025 Myfxbook Ltd. Hak Cipta Terpelihara.
PERINGATAN RISIKO TINGGI: Perdagangan pertukaran mata wang asing mempunyai risiko tinggi yang mungkin tidak sesuai untuk semua jenis pelabur. Leveraj menimbulkan risiko dan kerugian tambahan. Sebelum anda memutuskan untuk berdagang pertukaran mata wang asing, pertimbangkan dengan teliti objektif pelaburan, tahap pengalaman dan toleransi risiko anda. Anda berkemungkinan kehilangan sebahagian atau semua pelaburan awal anda. Jangan melaburkan wang yang anda tidak mampu untuk kehilangan. Didik diri anda tentang risiko yang berkaitan dengan perdagangan pertukaran asing, dan dapatkan nasihat daripada penasihat bebas kewangan atau cukai jika anda mempunyai sebarang pertanyaan mengenainya. Semua data dan maklumat yang disediakan adalah semata-mata untuk tujuan maklumat, dan bukan bertujuan untuk tujuan perdagangan atau nasihat. Prestasi masa lalu tidak semestinya menunjukkan hasil masa depan.